Transcode Therapeutics, Inc. 8-K

What Happened
Transcode Therapeutics, Inc. (RNAZ) announced it received a deficiency letter from the Nasdaq Listing Qualifications Department notifying the company it does not meet Nasdaq Capital Market's minimum stockholders' equity requirement under Listing Rule 5550(b)(1). The company reported stockholders' equity of $1,251,427 in its Quarterly Report on Form 10-Q for the period ended March 31, 2026, below the $2,500,000 threshold. The notice does not have an immediate effect on the listing; Nasdaq gave the company 45 calendar days (until July 3, 2026) to submit a plan to regain compliance, and may grant up to a 180-calendar-day extension to evidence compliance.

Key Details

• Reported stockholders' equity: $1,251,427 (Form 10-Q for quarter ended March 31, 2026).
• Nasdaq minimum required equity: $2,500,000 (Listing Rule 5550(b)(1)).
• Compliance timeline: 45 days to submit a Compliance Plan (deadline July 3, 2026); Staff may grant a 180-day extension to regain compliance.
• If Nasdaq staff rejects the plan or the company cannot regain compliance, a delisting determination could follow; the company may request a hearing before a Nasdaq Hearings Panel, which would stay delisting actions.

Why It Matters
A Nasdaq deficiency notice signals the company is below a key listing standard and must take actions—such as raising equity, improving results, or obtaining shareholder approval—to meet the rule. Failure to regain compliance could lead to delisting, which the company states would likely harm its operations, reputation and the market value and liquidity of its shares. The filing does not predict an outcome; it only describes the notice, required timelines, and the available appeal process.